2 citations
,
September 2022 in “Cureus” In this study conducted in the Makkah region, researchers observed that hair loss, mostly telogen effluvium, is a prevalent post-COVID-19 symptom, particularly among women and those with multiple health issues.
2 citations
,
September 2022 in “Drug Delivery” This study found that a transdermal drug delivery system using nanostructured lipid carriers and polymeric microneedles for β-sitosterol significantly enhanced hair growth in testosterone-induced alopecia rats, suggesting potential for treating androgenic alopecia.
5 citations
,
August 2022 in “Psychology Research and Behavior Management” This study found that nearly half of those perceiving hair loss reported a significant impact on their quality of life, highlighting potential benefits of seeking medical advice for diagnosis and treatment.
January 2022 in “مجلة جامعة المجمعه للعلوم الصحية” This case report describes a 54-year-old female erroneously treated for androgenetic alopecia with no improvement, later diagnosed with alopecia areata incognito through histopathological evaluation and appropriately treated.
December 2021 in “International Journal of Medicine in Developing Countries” This review examined existing studies on topical finasteride for androgenetic alopecia and noted inconsistent application of hair evaluation methods, suggesting a need for standardization in future research.
July 2021 in “Journal of Dermatology and Dermatologic Surgery” This study suggests an association between metabolic syndrome and androgenic alopecia severity, though this association was not statistically significant.
December 2020 in “Skin appendage disorders” This study describes a 17-year-old male with Klinefelter syndrome who developed androgenetic alopecia and showed a good response to treatment with oral minoxidil, finasteride, and low-level light therapy.
3 citations
,
February 2019 in “International Journal of Community Medicine and Public Health” This study found that off-label drug use was prevalent in Saudi Arabia, particularly among adults and geriatrics for depression and diabetes mellitus, with antidepressants and antidiabetics most commonly prescribed.
4 citations
,
January 2019 in “Egyptian Journal of Dermatology and Venereology” This study suggests that androgenetic alopecia moderately affects quality of life, with women experiencing a higher impact and showing a greater willingness to pay for treatment than men.
24 citations
,
July 2018 in “Drug Design Development and Therapy” This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.
1 citations
,
January 2018 in “The Open Dermatology Journal” This case report highlights a rare adverse event where a patient with inactive idiopathic papilledema experienced increased intracranial pressure after taking spironolactone, which resolved upon discontinuation of the drug.
1 citations
,
July 2017 in “Clinical research in dermatology” This review covers the pathogenesis, diagnosis, and potential new treatments for androgenetic alopecia but reports no new clinical findings, highlighting an ongoing need for effective therapies.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
115 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.
May 2013 in “Springer eBooks” 
88 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.
36 citations
,
June 2012 in “PubMed” This review discusses various treatments for androgenetic alopecia, including minoxidil, finasteride, dutasteride, ketoconazole, and experimental options, but reports limited clinical trial evidence for efficacy.
103 citations
,
June 2007 in “Endocrinology and Metabolism Clinics of North America” This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.
139 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This article reviews androgenetic alopecia in women, highlighting diagnosis criteria and noting that topical minoxidil is currently the only proven treatment for hair growth; it reports no clinical trial findings.
174 citations
,
November 2002 in “Expert Reviews in Molecular Medicine” This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.
229 citations
,
August 2002 in “Experimental Gerontology” This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.
179 citations
,
September 1998 in “BMJ” This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.
5 citations
,
October 1993 in “International Journal of Dermatology” This study found that 2% minoxidil led to moderate to dense hair growth in 80% of Middle-Eastern men treated for 48 weeks with early androgenic alopecia.
